載入...
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
Bevacizumab‐pemetrexed/cisplatin (BEV‐PEM/CIS) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV‐PEM/CIS has a narrow therapeutic window. Therefore, it is an attract...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Wiley
2019-08-01
|
| 叢編: | CPT: Pharmacometrics & Systems Pharmacology |
| 在線閱讀: | https://doi.org/10.1002/psp4.12415 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|